万邦德(002082) - 2026 Q1 - 季度业绩预告

Financial Performance - The estimated net profit for Q1 2026 is projected to be 16,500,000 CNY, representing a 985.40% increase compared to the same period last year [4]. - The net profit after deducting non-recurring gains and losses is expected to be 16,400,000 CNY, showing a growth of 2,174.55% year-over-year [4]. - Basic earnings per share (EPS) is anticipated to be 0.2697 CNY, up from 0.0249 CNY in the same period last year [4]. Business Strategy - The company is transitioning from generic drugs to innovative drugs, which has begun to yield positive results and new growth points [6]. - Increased internal management and enhanced receivables collection efforts have effectively accelerated cash flow [6]. Financial Caution - The financial data presented is preliminary and has not been audited by an accounting firm, cautioning investors to be aware of potential risks [5][7].